Therapeutic applications for subcutaneous triptans in the acute treatment of migraine

References

• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1):9-160
   PubMedGoogle Scholar
• Anthony M, Rasmussen BK. Migraine without aura. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The Headaches. New York, NY: Raven Press, 1993:255-61
   Google Scholar
• Saxena PR, Ferrari MD. 5HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10:200-4
   PubMed Web of Science ®Google Scholar
• Hargreaves RJ, Shepheard SL. Pathophysiology of migraine – new insights. Can J Neurol Sci 1999;26:S12-19
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 1990;30(Suppl 1):5-11
   PubMedGoogle Scholar
• Belvis R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009;4:70-81
   PubMedGoogle Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
   PubMed Web of Science ®Google Scholar
• Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia 2002;22:680-5
   PubMed Web of Science ®Google Scholar
• Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9
   PubMed Web of Science ®Google Scholar
• Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-18
   PubMed Web of Science ®Google Scholar
• Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554-60
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors know what migraine patients want from therapy? Headache 1999;39(Suppl 2):S20-6
   Google Scholar
• Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. Pharmacoeconomics 1997;11(Suppl 1):43-50
   PubMedGoogle Scholar
• Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000;55(9 Suppl 2):S29-35
   PubMed Web of Science ®Google Scholar
• Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 2007;47:475-9
   PubMed Web of Science ®Google Scholar
• Cady RK, Maizels M, Reeves DL, et al. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache 2009;49:386-94
   PubMed Web of Science ®Google Scholar
• Panconesi A, Pavone E, Franchini M, et al. Triptans: low utilization and high turnover in the general population. Cephalalgia 2010;30:576-81
   PubMed Web of Science ®Google Scholar
• Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:1435-44
   PubMed Web of Science ®Google Scholar
• Sumavel DosePro (sumatriptan injection) for subcutaneous use. Prescribing information. San Diego, CA: Zogenix, Inc., 2011
   Google Scholar
• Dahlof C. Update on sumatriptan: new progress in migraine treatment. Future Medicine – Therapy 2005;2:349-56
   Google Scholar
• The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Eng J Med 1991;325:316-21
   PubMed Web of Science ®Google Scholar
• Cady RK, Wendt JK, Kirchner JF, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
   PubMed Web of Science ®Google Scholar
• Salonen R. Drug comparisons: why are they so difficult? Cephalalgia 2000;20(Suppl 2):25-32
   PubMed Web of Science ®Google Scholar
• Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996;28:171-8
   PubMedGoogle Scholar
• Tfelt-Hansen P. Early responses in randomized clinical trials of triptans in acute migraine treatment. Are they clinically relevant? A comment. Headache 2010;50:1198-200
   PubMed Web of Science ®Google Scholar
• Farmer K, Cady R, Bleiberg J, et al. A pilot study to measure cognitive efficiency during migraine. Headache 2000;40:657-61
   PubMed Web of Science ®Google Scholar
• Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia 2009;29(Suppl 3):15-21
   PubMed Web of Science ®Google Scholar
• Aurora SK, Barrodale PM, McDonald SA, et al. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlöf C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995;35:387-96
   PubMed Web of Science ®Google Scholar
• National Headache Foundation. Migraine patient survey, April 2010. Available at: http://www.headaches.org/NHF_Programs/NHF_Web_Surveys [Last accessed 27 November 2010]
   Google Scholar
• Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 2006;46:57-63
   PubMed Web of Science ®Google Scholar
• Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975;2:57-63
   PubMed Web of Science ®Google Scholar
• Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984;17:67-75
   PubMed Web of Science ®Google Scholar
• Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose-comparison study. Acta Neurol Scand 1993;88:63-9
   PubMed Web of Science ®Google Scholar
• Bousser MG, D’Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993;234:211-16
   PubMed Web of Science ®Google Scholar
• Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia 1999;19:16-19
   PubMed Web of Science ®Google Scholar
• Welch KM, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 2000;20:687-95
   PubMed Web of Science ®Google Scholar
• Schoenen J. Acute migraine therapy – the newer drugs. Curr Opin Neurol 1997;10:237-43
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-25
   PubMed Web of Science ®Google Scholar
• O’Quinn S, Davis RL, Gutterman DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19:223-31
   PubMed Web of Science ®Google Scholar
• Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 2001;41:862-6
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia 1997;17:31-6
   PubMed Web of Science ®Google Scholar
• Gross ML, Kay J, Turner AM, et al. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994;34:559-63
   PubMed Web of Science ®Google Scholar
• Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX® STATdose System. Clin Ther 1996;18:687-99
   PubMed Web of Science ®Google Scholar
• Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011;51:1202-11
   PubMed Web of Science ®Google Scholar
• Kilminster SG, Dowson AJ, Tepper SJ, et al. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache 2006;46:553-62
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin 2011;27:2185-91
   Google Scholar